Results 131 to 140 of about 113,823 (359)
Treatment of rare factor deficiencies other than hemophilia.
Blood, 2019 The deficiency of fibrinogen, prothrombin, factor V (FV), FVII, FVIII, FIX, FX, FXI, and FXIII, called rare coagulation disorders (RCDs), may result in coagulopathies leading to spontaneous or posttrauma and postsurgery hemorrhages.
M. Menegatti, F. Peyvandi
semanticscholar +1 more source
Systemic lupus erythematosus with acquired hemophilia A: A case report and literature review. [PDF]
, 2023 Ye Mei +4 more
openalex +1 more source
Haemophilia, EarlyView.ABSTRACT Background The Natural History Study of the Safety, Effectiveness, and Practice of Treatment for People with Haemophilia (ATHN 7) monitors use of contemporary haemophilia therapies, including emicizumab, a bispecific antibody substituting for activated factor (F)VIII in people with haemophilia A (HA).
Tyler W. Buckner +12 more
wiley +1 more source
Successful management of concurrent acquired hemophilia A and a lupus anticoagulant in a pediatric hematopoietic stem cell transplant patient [PDF]
, 2018 LaQuita M. Jones +7 more
openalex +1 more source
Haemophilia, EarlyView.ABSTRACT Introduction Radioactive synovectomy (RSO) is an alternative to arthroscopic synovectomy (AR), for treating synovitis. RSO reduces the number of hemarthroses, being less invasive and less costly. Objective To analyse the costs of RSO compared to AR in the treatment of patients with haemophilia in Brazil, using real‐world data (RSO) and ...
Sylvia Thomas +4 more
wiley +1 more source
Blood, 2019 Results from the main parts (24 weeks) of two concizumab phase 2 trials are presented: explorer4 (NCT03196284) in hemophilia A (HA) or B (HB) with inhibitors (HAwI/HBwI); explorer5 (NCT03196297) in HA without inhibitors.
A. Shapiro +14 more
semanticscholar +1 more source
Family medicine, 2018 Algorithms of hemostatic therapy of hemophilia disease are presented.The treatment is based onsubstitute therapy by blood clotting factorsand other hemostatic drugs. Schemes for calculationof the hemostaticdrug doses, intervals between the doses, and duration of treatment forthe mostincident manifestations of the hemorrhagic syndrome arepresented ...
null С. В. Видиборець +2 more
openaire +2 more sources
HAEMFIX: Impact of Switching From SHL‐FIX to EHL‐FIX in Patients With Haemophilia B
Haemophilia, EarlyView.ABSTRACT Introduction Haemophilia B is an X‐linked recessive bleeding disorder caused by coagulation factor IX (FIX) deficiency. Treatment involves intravenous replacement of FIX. Recently, extended half‐life (EHL) FIX products have been introduced alongside standard half‐life (SHL) products to optimize therapy. Aim This study evaluated bleeding rates,
Jasmin Lonardi +11 more
wiley +1 more source
Haemophilia, EarlyView.ABSTRACT Background In patients with unexplained bleeding and normal haemostatic parameters, heritable disorders of connective tissue (HDCT) may be an underlying cause due to vascular fragility, as observed in Ehlers–Danlos syndrome (EDS) or Marfan syndrome (MS). This study aims to investigate the molecular profile of patients with joint hypermobility (
Perla Bandini +11 more
wiley +1 more source